Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1993 1
1996 2
1998 1
2001 1
2005 1
2009 1
2010 1
2013 1
2014 2
2015 1
2016 2
2017 1
2018 1
2019 1
2020 1
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Among authors: anton torres a. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer.
Wuerstlein R, Ellis P, Montemurro F, Antón Torres A, Delaloge S, Zhang Q, Wang X, Wang S, Shao Z, Li H, Rachman A, Vongsaisuwon M, Liu H, Fear S, Peña-Murillo C, Barrios C. Wuerstlein R, et al. Among authors: anton torres a. ESMO Open. 2022 Oct;7(5):100561. doi: 10.1016/j.esmoop.2022.100561. Epub 2022 Sep 7. ESMO Open. 2022. PMID: 36084395 Free PMC article. Clinical Trial.
Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study.
Llombart-Cussac A, Anton-Torres A, Rojas B, Andrés R, Martinez N, Rodríguez CA, Marin S, Puértolas T, González AF, Fernández-Murga ML, Hagen C, Ruiz-Borrego M. Llombart-Cussac A, et al. Among authors: anton torres a. Cancers (Basel). 2023 Feb 28;15(5):1529. doi: 10.3390/cancers15051529. Cancers (Basel). 2023. PMID: 36900321 Free PMC article.
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Salvador Bofill J, Moreno Anton F, Rodriguez Sanchez CA, Galve Calvo E, Hernando Melia C, Ciruelos Gil EM, Vidal M, Jiménez-Rodriguez B, De la Cruz Merino L, Martínez Jañez N, Villanueva Vazquez R, de Toro Salas R, Anton Torres A, Alvarez Lopez IM, Gavila Gregori J, Quiroga Garcia V, Vicente Rubio E, De la Haba-Rodriguez J, Gonzalez-Santiago S, Diaz Fernandez N, Barnadas Molins A, Cantos Sanchez de Ibargüen B, Delgado Mingorance JI, Bellet Ezquerra M, de Casa S, Gimeno A, Martin M. Salvador Bofill J, et al. Among authors: anton torres a. Breast. 2022 Dec;66:77-84. doi: 10.1016/j.breast.2022.09.006. Epub 2022 Sep 28. Breast. 2022. PMID: 36206609 Free PMC article. Clinical Trial.
Patient Perspective on the Management of Cancer Pain in Spain.
García-Foncillas J, Antón-Torres A, Caballero-Martínez F, Campos FJ, Feyjoo M, de Liaño AG, Monge D, Camps C. García-Foncillas J, et al. Among authors: anton torres a. J Patient Exp. 2020 Dec;7(6):1417-1424. doi: 10.1177/2374373520978872. Epub 2021 Jan 3. J Patient Exp. 2020. PMID: 33457596 Free PMC article.
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, Calvo L, García-Asenjo JA, Palacios J, Chacon JI, Ruiz A, De la Haba-Rodriguez J, Segui-Palmer MA, Cirauqui B, Margeli M, Plazaola A, Barnadas A, Casas M, Caballero R, Carrasco E, Rojo F. Alba E, et al. Among authors: anton torres a. Oncologist. 2016 Feb;21(2):150-5. doi: 10.1634/theoncologist.2015-0312. Epub 2016 Jan 19. Oncologist. 2016. PMID: 26786263 Free PMC article.
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
Moreno V, Barretina-Ginesta MP, García-Donas J, Jayson GC, Roxburgh P, Vázquez RM, Michael A, Antón-Torres A, Brown R, Krige D, Champion B, McNeish I. Moreno V, et al. Among authors: anton torres a. J Immunother Cancer. 2021 Dec;9(12):e003645. doi: 10.1136/jitc-2021-003645. J Immunother Cancer. 2021. PMID: 34893524 Free PMC article. Clinical Trial.
Brain metastasis in basaloid undifferentiated anal carcinoma: A case report.
Hernando-Cubero J, Alonso-Orduña V, Hernandez-Garcia A, DE Miguel AC, Alvarez-Garcia N, Anton-Torres A. Hernando-Cubero J, et al. Among authors: anton torres a. Oncol Lett. 2014 Apr;7(4):1276-1278. doi: 10.3892/ol.2014.1845. Epub 2014 Jan 31. Oncol Lett. 2014. PMID: 24944707 Free PMC article.
A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer.
Díaz-Rubio García E, Abad Esteve A, Antón Torres A, Aranda Aguilar E, Benavides Orgaz M, Carrato Mena A, Cervantes Ruipérez A, Feliu Batle J, García Alfonso P, García Foncillas J, Grávalos Castro C, Navarro García M, Rivera Herrero F, Tabernero Caturla JM. Díaz-Rubio García E, et al. Among authors: anton torres a. Clin Transl Oncol. 2005 Jan-Feb;7(1):3-11. doi: 10.1007/BF02710019. Clin Transl Oncol. 2005. PMID: 15890149 Review.
23 results